SCHEMBL1973506

SCHEMBL1973506

COc1cc(OC)c2c(c1)O[C@H](c1ccc(O)c(O)c1)[C@@H](O)C2C

nearest known ligand 0.47

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ XDH P47989 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ NR3C1 P04150 1/20 0.42
▸ ALOX5 P09917 1/20 0.41
▸ PTPN1 P18031 1/20 0.41
▸ PPARG P37231 1/20 0.41
▸ PPARD Q03181 1/20 0.41
▸ CYP19A1 P11511 1/20 0.41
▸ ABCB1 P08183 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1975182 0.90 HSD17B10 (0.44) XDHALDH1A1CYP3A4MAPK1CYP19A1
SCHEMBL1430855 0.87 XDH (0.43) XDHALDH1A1CYP3A4MAPK1NR3C1
SCHEMBL14244672 0.82 SNCA (0.57) XDHALDH1A1CYP3A4MAPK1
SCHEMBL12597042 0.78 SNCA (0.52) XDHALDH1A1CYP3A4MAPK1
SCHEMBL6262437 0.77 HSD17B10 (0.56) XDHALDH1A1CYP3A4MAPK1
SCHEMBL2433863 0.77 HSD17B10 (0.56) XDHALDH1A1CYP3A4MAPK1
SCHEMBL6262441 0.77 HSD17B10 (0.56) XDHALDH1A1CYP3A4MAPK1
SCHEMBL6729179 0.77 XDH (0.58) XDHALDH1A1CYP3A4MAPK1ABCB1
SCHEMBL25246785 0.76 CYP3A4 (0.78) ALDH1A1CYP3A4MAPK1ABCB1
SCHEMBL862416 0.76 CYP3A4 (0.78) ALDH1A1CYP3A4MAPK1ABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210015964-A1 METHOD OF FORMING AND USING A HEMOSTATIC HYDROCOLLOID UNITED HEALTH PRODUCTS INC (US) 2021-01-21 — — US disclosed
US-20140046277-A1 FAST-CLOTTING WOUND DRESSINGS GAMMA THERAPEUTICS, INC. 2014-02-13 — — US disclosed
US-8557874-B2 Hemostatic material EPIC WOUND CARE, INC. (US) 2013-10-15 — — US disclosed
WO-2012142317-A1 FAST-CLOTTING WOUND DRESSINGS GAMMA THERAPEUTICS, INC (US) 2012-10-18 — — WO disclosed
EP-1803473-B1 Adhesive including medicament UNIV LOMA LINDA MED (US) 2011-06-22 — — EP disclosed
WO-2009070684-A2 HEMOSTATIC MATERIAL BAGGETT RICHARD W (US) 2009-06-04 — — WO disclosed
US-20090136562-A1 Hemostatic Material UNITED ECOENERGY CORP. 2009-05-28 — — US disclosed
WO-2009002768-A2 LIQUID BANDAGE MEDSPRING GROUP, INC. (US) 2008-12-31 — — WO disclosed
US-20080031929-A1 LIQUID BANDAGE MEDSPRING GROUP, INC. 2008-02-07 — — US disclosed
EP-1803473-A2 Adhesive including medicament Loma Linda University Medical Center (US) 2007-07-04 — — EP disclosed
US-20070026052-A1 Hemostatic material UNITED ECOENERGY CORP. 2007-02-01 — — US disclosed
US-20050123588-A1 Deployable multifunctional hemostatic agent LOMA LINDA UNIVERSITY MEDICAL CENTER 2005-06-09 — — US disclosed
US-20030044380-A1 Adhesive including medicament LOMA LINDA UNIVERSITY 2003-03-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030044380-A1 Adhesive including medicament ICAM1, VCAM1, EPCAM XDH 3834/4885ALDH1A1 473/4885CYP3A4 4815/4885
US-20080031929-A1 LIQUID BANDAGE FGB, F2, F8 XDH 2722/4885ALDH1A1 2642/4885CYP3A4 3316/4885
US-20050123588-A1 Deployable multifunctional hemostatic agent FGB, CHIT1, CHIA XDH 4329/4885ALDH1A1 3379/4885CYP3A4 3864/4885
US-20070026052-A1 Hemostatic material F2, F8, F3 XDH 2417/4885ALDH1A1 2436/4885CYP3A4 2679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback